Petros Pharmaceuticals, Inc. (PTPI)
OTCMKTS
· Delayed Price · Currency is USD
0.0310
-0.0027 (-8.01%)
At close: Jun 13, 2025
Petros Pharmaceuticals Revenue
Petros Pharmaceuticals had revenue of $5.11M in the twelve months ending March 31, 2025, up 54.70% year-over-year. In the year 2024, Petros Pharmaceuticals had annual revenue of $5.11M, down -12.20%.
Revenue
5.11M
Revenue Growth
+54.70%
P/S Ratio
0.19
Revenue / Employee
284.00K
Employees
18
Market Cap
965.96K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Petros Pharmaceuticals News
- 24 days ago - Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets - Accesswire
- 25 days ago - Petros Pharmaceuticals partners with Innolitics to accelerate SaaS platform development - Seeking Alpha
- 25 days ago - Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer - Accesswire
- 5 weeks ago - Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform - Accesswire
- 6 weeks ago - Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches - Accesswire
- 6 weeks ago - Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms - Accesswire
- 3 months ago - Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications - Accesswire
- 3 months ago - Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study - Accesswire